Literature DB >> 31029489

Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth.

Meredith A Hackel1, Masakatsu Tsuji2, Yoshinori Yamano3, Roger Echols4, James A Karlowsky5, Daniel F Sahm6.   

Abstract

In 2017, the Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing approved the use of iron-depleted cation-adjusted Mueller-Hinton broth (ID-CAMHB) prepared with Chelex® 100 resin (Bio-Rad Laboratories, Hercules, CA) to determine MICs for cefiderocol. The current study examined the reproducibility of cefiderocol MICs generated for 19 clinical isolates of Gram-negative bacilli, with CAMHB produced by three manufacturers; each of the 19 isolates was tested for 10 replicates in ID-CAMHB from each manufacturer. When analyzed by individual media lot, greater than 95% of MIC results were within ± one doubling-dilution of the mode for each of the 19 isolates tested. The remaining 5.0% of MIC results were within ± two doubling-dilutions of the modal MIC. For all media lots combined, 92.2% of MIC results were within ± one doubling-dilution of the modal MIC for each isolate, 99.8% were within ± two doubling-dilutions and 100% were within three doubling-dilutions.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cation-adjusted Mueller-Hinton broth; Cefiderocol; Gram-negative bacilli; Iron-depleted; MIC; Reproducibility; Siderophore

Mesh:

Substances:

Year:  2019        PMID: 31029489     DOI: 10.1016/j.diagmicrobio.2019.03.003

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  15 in total

1.  Genome Mining and Metabolomics Unveil Pseudonochelin: A Siderophore Containing 5-Aminosalicylate from a Marine-Derived Pseudonocardia sp. Bacterium.

Authors:  Fan Zhang; René F Ramos Alvarenga; Kurt Throckmorton; Shaurya Chanana; Doug R Braun; Jen Fossen; Miao Zhao; Sue McCrone; Mary Kay Harper; Scott R Rajski; Warren E Rose; David R Andes; Michael G Thomas; Tim S Bugni
Journal:  Org Lett       Date:  2022-06-01       Impact factor: 6.072

2.  Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in Enterobacter cloacae Due to AmpC R2 Loop Deletion.

Authors:  Akito Kawai; Christi L McElheny; Alina Iovleva; Ellen G Kline; Nicolas Sluis-Cremer; Ryan K Shields; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 3.  New Perspectives on Antimicrobial Agents: Cefiderocol.

Authors:  Erin K McCreary; Emily L Heil; Pranita D Tamma
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

4.  Occurrence of High Levels of Cefiderocol Resistance in Carbapenem-Resistant Escherichia coli before Its Approval in China: a Report from China CRE-Network.

Authors:  Qi Wang; Longyang Jin; Shijun Sun; Yuyao Yin; Ruobing Wang; Fengning Chen; Xiaojuan Wang; Yawei Zhang; Jun Hou; Yumei Zhang; Zhijie Zhang; Liuchun Luo; Zhusheng Guo; Zhenpeng Li; Xin Lin; Lei Bi; Hui Wang
Journal:  Microbiol Spectr       Date:  2022-04-28

5.  Activity of Cefiderocol Against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Endemic to Medical Centers in New York City.

Authors:  Alejandro Iregui; Zeb Khan; David Landman; John Quale
Journal:  Microb Drug Resist       Date:  2020-02-07       Impact factor: 3.431

6.  Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin.

Authors:  Takafumi Sato; Kenji Yamawaki
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079

7.  Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia.

Authors:  M Biagi; A Vialichka; M Jurkovic; T Wu; A Shajee; M Lee; S Patel; R E Mendes; E Wenzler
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

8.  Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an In Vitro Chemostat Model.

Authors:  Shuhei Matsumoto; Sachi Kanazawa; Takafumi Sato; Yoshinori Yamano
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 9.  Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data.

Authors:  Daniele Roberto Giacobbe; Eugenio Ciacco; Corrado Girmenia; Federico Pea; Gian Maria Rossolini; Giovanni Sotgiu; Carlo Tascini; Mario Tumbarello; Pierluigi Viale; Matteo Bassetti
Journal:  Infect Drug Resist       Date:  2020-12-29       Impact factor: 4.003

10.  Development of a Broth Microdilution Method for Exebacase Susceptibility Testing.

Authors:  Jun T Oh; Jane E Ambler; Cara Cassino; Raymond Schuch
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.